{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062034","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.071076+00:00","generated_at":"2026-06-08T06:59:33.484275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dianthus reports Q3 net loss $14.8M; positive Phase 1 data for DNTH103, cash $189.9M","bullets":["Net loss of $14.8M ($3.78 per share); R&D expenses $8.0M, G&A $8.7M including $4.0M severance.","Cash, equivalents, and investments $189.9M at Sept. 30, 2023; runway into Q2 2026.","Phase 1 data: ~60-day half-life, potent classical complement inhibition, no serious adverse events.","Plan to start Phase 2 trials: gMG in Q1 2024, followed by MMN (1H24) and CIDP (2H24).","Completed merger with Magenta Therapeutics and $72M private placement led by Fidelity and others."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062034","json":"https://secwatch.observer/filing/0000950170-23-062034.json","markdown":"https://secwatch.observer/filing/0000950170-23-062034.md","text":"https://secwatch.observer/filing/0000950170-23-062034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017023062034/0000950170-23-062034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017023062034/dnth-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:59:33.484275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f571e11d0e937a288b31b42ba4670b45f1fc8cc1","claim":"Dianthus Therapeutics, Inc. /DE/ reported third quarter ending September 30, 2023 results: net income $14.8 million, EPS $3.78 net loss per share (basic and diluted).","evidence_excerpt":"Net loss for the quarter ended September 30, 2023 was $14.8 million or $3.78 net loss per share (basic and diluted).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017023062034/0000950170-23-062034-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ending September 30, 2023"},{"label":"Net income","value":"$14.8 million"},{"label":"EPS","value":"$3.78 net loss per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}